Merck & Co Inc


  • *CEO says Roche committed to Switzerland despite franc rise. While cross-town rival Novartis has said it will review its Swiss cost base, Roche Chief Executive Severin Schwan said his company had no plans to move operations. "I continue to believe that Switzerland and Basel offer a very good framework for our business," Schwan told reporters.

  • Jan 27- Bristol-Myers Squibb Co on Tuesday said profits could fall as much as 16 percent in 2015, a worse forecast than Wall Street had expected, as the stronger dollar takes a toll on U.S. drugmakers. Bristol-Myers, whose shares fell almost 2 percent in premarket trading, said it earned $13 million, or 1 cent per share, in the fourth quarter. Revenue fell 4 percent to...

  • Robert Califf, a top cardiologist and researcher, to oversee its drug, medical device and tobacco policy in what experts said is a coup for the FDA. "This is a great catch for the FDA," said Dr. Califf has run countless clinical studies, published more than 1,000 papers, served as an FDA adviser and has twice been interviewed as a potential FDA commissioner.

  • Jan 20- Johnson& Johnson surprised investors by detailing the degree to which a strong dollar will hurt sales abroad this year, and industry watchers say Wall Street is underestimating the likely hit to other U.S.-based rivals such as Pfizer Inc and Merck& Co.. He predicted the stronger dollar will take a bigger bite out of other drugmakers' earnings than many...

  • Davos: Who needs a 'wake up call'?  Tuesday, 20 Jan 2015 | 11:25 AM ET

    Discussing the current state of Europe at Davos 2015, Karl-Ludwig Kley, chairman of Merck says the lack of coordination and cohesion in European businesses is the current problem.Meanwhile political leaders need a wake-up call.

  • If you could be any other CEO, who would you be? Friday, 16 Jan 2015 | 12:14 PM ET
    Tesla Motors CEO Elon Musk speaking in Detroit, January 13, 2015.

    At the J.P. Morgan Healthcare Conference, executives name the CEOs they'd most like to replace.

  • J&J Ebola vaccine gets $115M to speed development Friday, 16 Jan 2015 | 8:57 AM ET
    A worker in vaccine production at drugmaker GlaxoSmithKline in Saint-Amand-les-Eaux, France.

    Johnson & Johnson said that newly formed groups supporting work on its experimental Ebola vaccine would receive $115 million to speed development.

  • SAN FRANCISCO/ WASHINGTON Jan 15- U.S. healthcare executives say Obamacare is likely here to stay, despite repeated calls from Republican lawmakers for repeal of the 2010 law aimed at providing health coverage for millions of uninsured Americans. Top executives who gathered in San Francisco this week for the annual J.P. Morgan Healthcare conference, say that...

  • Healthcare Executives on a Saturday  Thursday, 15 Jan 2015 | 10:30 AM ET

    Healthcare executives talk about their weekend activities.

  • 9 stocks that'll get you through the storm Thursday, 15 Jan 2015 | 10:17 AM ET

    These nine stocks are faring well despite the tumultuous market, USA Today reports.

  • SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....

  • HALFTIME FINAL TRADES 1/14/15 Wednesday, 14 Jan 2015 | 2:31 PM ET
  • Midday movers: Aetna, Ocwen Financial, GoPro & more Tuesday, 13 Jan 2015 | 1:13 PM ET

    Some of Tuesday's midday movers:

  • SAN FRANCISCO, Jan 12- Eli Lilly and Co said on Monday that U.S. insurers are increasing pressure on the price of diabetes medications as they switch coverage from certain drugs to others to trim costs. "We've definitely seen increased price competition, more by payers than the companies themselves," Lilly Chief Financial Officer Derica Rice said on Monday in an...

  • 11 ways to play biotech Monday, 12 Jan 2015 | 6:59 PM ET

    Traders on CNBC's "Fast Money" outlined their strongest plays in the ever-volatile biotechnology space.

  • Merck CEO: Deals create value  Monday, 12 Jan 2015 | 4:27 PM ET

    Merck CEO Ken Frazier plans to focus on its specialized area strategy in 2015, with CNCB's Meg Tirrell.

  • ZURICH/ LOS ANGELES Jan 12- Roche Holding will acquire a majority stake in molecular and genomic analysis business Foundation Medicine, it said on Monday, signalling its determination to expand in cancer immunotherapy by paying a hefty mark-up on the U.S. company's current price. The deal will help the world's largest maker of cancer drugs push ahead in...

  • Jan 9- An experimental drug from Sanofi SA and Regeneron Pharmaceuticals was found to be effective in lowering "bad" cholesterol even when administered once every four weeks, instead of every two weeks. Sanofi SA and Regeneron are in a fierce race with Pfizer and Amgen Inc to bring their PCSK9 inhibitor to the market, which is expected to be worth billions if these...

  • Cramer Remix: Party with these rock star stocks Thursday, 8 Jan 2015 | 7:15 PM ET
    Jim Cramer on Mad Money.

    "Mad Money" host Jim Cramer on the players that could keep tearing it up in 2015.

  • S&P 500 records longest loss streak since late 2013 Tuesday, 6 Jan 2015 | 4:37 PM ET
    Traders work on the floor of the New York Stock Exchange, Oct. 29, 2014.

    Stocks fell Tuesday as investors fretted the implications of crude's failure to find a floor.